MONTREAL, Jan. 23, 2026 /PRNewswire/ - Alithya Group inc. (TSX: ALYA) ("Alithya") will report on February 13, 2026, its financial results for the third quarter of fiscal 2026 ended December 31, 2025. Alithya will host a conference call, followed by a question-and-answer period for the financial community at 9:00 a.m. (Eastern time). Financial statements, MD&A, press release, and presentation will be posted on the Investors page of Alithya's website. Conference call Date: Friday, February 13, 2026 ...

Core Viewpoint - Investors are evaluating Hackett Group (HCKT) and CRA International (CRAI) to determine which stock presents a better value opportunity for investment [1] Valuation Metrics - HCKT has a forward P/E ratio of 11.97, while CRAI has a forward P/E of 25.31, indicating HCKT may be undervalued compared to CRAI [5] - HCKT's PEG ratio is 1.09, which is lower than CRAI's PEG ratio of 1.58, suggesting HCKT offers better value considering expected earnings growth [5] - HCKT's P/B ratio is 5.57, compared to CRAI's P/B of 7.27, further supporting HCKT's valuation advantage [6] Earnings Outlook - Both HCKT and CRAI have a Zacks Rank of 2 (Buy), indicating a positive earnings outlook due to favorable analyst estimate revisions [3] - HCKT is considered the superior value option based on the discussed valuation metrics, despite both companies having solid earnings prospects [7]

Core Insights - Zacks Premium offers various tools to enhance stock market investment confidence, including daily updates, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores provide a rating system for stocks based on value, growth, and momentum, helping investors identify securities likely to outperform the market in the short term [3][4] - Stocks are rated from A to F, with A indicating the highest potential for outperformance [4] Value Score - The Value Score identifies attractive stocks using financial ratios like P/E and Price/Sales, focusing on undervalued stocks [4] Growth Score - The Growth Score assesses a company's financial health and future outlook, focusing on earnings and sales growth [5] Momentum Score - The Momentum Score tracks price trends and earnings estimates to identify favorable investment opportunities in high-momentum stocks [6] VGM Score - The VGM Score combines Value, Growth, and Momentum Scores, providing a comprehensive rating for stocks [7] Zacks Rank - The Zacks Rank is a proprietary model based on earnings estimate revisions, with 1 (Strong Buy) stocks historically yielding an average annual return of +23.9% since 1988, outperforming the S&P 500 [8][10] - There are over 800 top-rated stocks available, making it essential to utilize Style Scores for better selection [9] Stock to Watch: Accenture (ACN) - Accenture is a leading consulting firm with a revenue increase of 7.4% in fiscal 2025, currently rated 3 (Hold) with a VGM Score of B [12] - The company is favored by growth investors, with a Growth Style Score of B and a forecasted earnings growth of 7.3% for the current fiscal year [13] - Recent upward revisions in earnings estimates and a Zacks Consensus Estimate increase to $13.87 per share highlight Accenture's potential [13]

Core Insights - FTI Consulting, Inc. (FCN) shares have increased by 4.3% over the past month, outperforming the industry growth of 3.3% [1] - Earnings for 2025 and 2026 are projected to grow by 5.5% and 9.1%, respectively [1] Group 1: Company Performance - FCN's diverse consulting services span Corporate Finance and Restructuring, Economic consulting, Forensic and Litigation consulting, Technology consulting, and Strategic Communications, contributing to its broad revenue streams [2] - The company has a skilled and diverse workforce that enhances its service quality and investor appeal, supported by strategic investments in employee development and competitive compensation [3] - FCN has consistently engaged in share buybacks, repurchasing shares worth $46.1 million in 2021, $85.4 million in 2022, $21 million in 2023, and $10.2 million in 2024, which boosts shareholder value [4] Group 2: Financial Health - FCN reported a current ratio of 1.85 in Q3 2025, surpassing the industry average of 1.19, indicating strong liquidity to meet short-term obligations [5] - The company does not currently pay cash dividends, which may deter dividend-seeking investors [6] Group 3: Market Position - FCN holds a Zacks Rank of 3 (Hold), while competitors Information Services Group (III) and Charles River Associates (CRAI) have better rankings of 2 (Buy) [7][8] - Information Services Group has a long-term earnings growth expectation of 18.5% and a trailing four-quarter earnings surprise of 15.9% on average [7] - Charles River Associates has a long-term earnings growth expectation of 16% with a trailing four-quarter earnings surprise of 15% on average [8]

Key Takeaways Willdan's Energy segment drove growth in the first nine months of 2025, with contract revenues up 20%.WLDN is benefiting from rising data center power demand, boosting planning and engineering services.Willdan's APG acquisition expanded power engineering capabilities, supporting backlog growth into 2026.Shares of Willdan Group, Inc. ((WLDN) have surged 27.7% in the past three months, outperforming the Zacks Business - Services industry’s 2.1% fall. The S&P 500 rose 6.2% over the same timeframe ...

Core Insights - Dark Horse Consulting Group (DHCG) has announced the acquisition of Bruder Consulting & Venture Group (BCVG), enhancing its capabilities in the biotherapy sector, particularly in regenerative medicine, orthopedic, wound care, and plastic and reconstructive surgery markets [1][2] - The acquisition aims to accelerate the development and commercialization of biotherapeutic drugs, expanding DHCG's service offerings to include regenerative medicine, tissue repair, and biomaterials [2] - The integration of BCVG into DHCG is expected to enrich the company's expertise and improve its ability to provide comprehensive solutions to research institutions and investors [2] Company Overview - Dark Horse Consulting Group is a global consulting firm established in 2014, with offices in North America, Europe, and Asia-Pacific, focusing on accelerating the development and delivery of cell and gene therapies [3] - DHCG's consulting expertise spans the entire biopharmaceutical value chain, including strategic planning, operational management, quality control, regulatory affairs, manufacturing, modeling and analysis, supply chain management, market entry, and business optimization [3] - The company comprises three business units: DHC, BioTechLogic, and Converge Consulting, with BCVG now operating as a specialized department under DHC [3] Bruder Consulting & Venture Group Overview - Bruder Consulting & Venture Group is a full-service strategic consulting firm specializing in orthopedic, wound care, and plastic and reconstructive surgery markets, with significant expertise in the discovery, development, clinical design, and regulatory approval processes for bioproducts, medical devices, and combination products [4] - The BCVG team has completed over 900 projects for more than 150 companies globally and has led or supported licensing and acquisition transactions valued at over $2 billion [4]

Core Viewpoint - Accenture plc (NYSE:ACN) is recognized as a notable AI stock on Wall Street, with a "Buy" rating initiated by Truist Securities and a price target of $317, highlighting its potential in enterprise modernization trends, particularly in GenAI [1]. Group 1: Business Growth and Valuation - Analysts project that ACN's business mix will support mid-single-digit growth and stable margins over a multi-year horizon, despite concerns regarding GenAI's impact on existing business [2]. - The stock is currently trading at a significant discount to its historical average, primarily due to fears of GenAI cannibalizing existing business [3]. Group 2: Strategic Partnerships and Legacy Revenue - Accenture's strategic partnerships with leading frontier labs and its involvement in the broader GenAI ecosystem are viewed as positive factors for the company's future [4]. - The company has a proven track record of successfully cannibalizing legacy revenue streams, suggesting that patient investors may see rewards over time [4].

Financial Data and Key Metrics Changes - Consolidated revenue for Q2 was approximately $117.7 million, reflecting an 18.4% decline year-over-year on a constant currency basis [19][20] - Adjusted EBITDA was $4 million, resulting in a 3.4% adjusted EBITDA margin, despite a GAAP net loss of $12.7 million due to one-time expenses [19][20] - Gross margin decreased to 37.1% from 38.5% in the prior year, impacted by healthcare costs and holiday pay [20][21] Business Line Data and Key Metrics Changes - On-demand segment revenue was $43 million, down 18.4% year-over-year, with segment-adjusted EBITDA at $4.1 million, a margin of 9.5% [25] - Consulting segment revenue declined 28.8% to $42.6 million, with segment-adjusted EBITDA at $4.5 million, a margin of 10.4% [25] - Europe and Asia Pac segment revenue grew 0.6% to $20.1 million, maintaining stable gross margins [25][26] Market Data and Key Metrics Changes - North America saw improved pipeline activity due to expanded go-to-market initiatives, while Europe and Asia Pac segments delivered growth [12][17] - Outsourced services revenue remained steady year-over-year at $9.4 million, with improved gross margins [26] Company Strategy and Development Direction - The company aims to align its cost structure with current revenue levels, refocus on-demand offerings, and scale its consulting business [6][7] - Emphasis on providing relevant skills and solutions to clients at competitive prices to enhance value [6][9] - The integration of Reference Point is expected to enhance collaboration and strengthen focus on CFO Advisory and Digital Transformation [13][14] Management's Comments on Operating Environment and Future Outlook - The management acknowledges a challenging market but believes in the potential for growth due to a large market of client needs [6][11] - Future strategies will focus on improving sales execution and optimizing talent to meet client demands [51][52] - The company expects Q3 revenue to be between $105-$110 million, with gross margins projected at 35%-36% [27][28] Other Important Information - The company has a strong balance sheet with $89.8 million in cash and no outstanding debt, allowing for balanced capital allocation [26] - A reduction in force was executed, impacting 5% of management and administrative headcount, expected to yield annual savings of $6-$8 million [22][23] Q&A Session Summary Question: Areas where AI is impacting finance and accounting roles - Management noted that operational accounting roles are most affected by AI and automation, with ongoing experimentation by clients [31][33] Question: Impact of AI on decision-making - Management clarified that while AI is causing clients to reassess roles, it is not significantly delaying decisions [57][59] Question: Clarification on SG&A expenses - SG&A expenses for Q3 are expected to be $40-$42 million, excluding $6-$7 million in non-cash and restructuring costs [47][49] Question: Impact of healthcare costs on margins - Healthcare costs had a significant impact, estimated at over $1 million, affecting both SG&A and gross margins [48][62] Question: Broader strategic focus for the next 12-24 months - The company will focus on aligning cost structures, enhancing on-demand services, and growing the consulting segment [51][52]

Investment Strategy Overview - The investment approach emphasizes Richard Driehaus' "buy high and sell higher" theory, which aims to capture stocks with strong momentum for further upside potential [1] - Stocks like Kinross Gold Corporation (KGC) and Willdan Group, Inc. (WLDN) have shown significant upward trends, with share prices increasing by 203.8% and 172.2% respectively last year [2] Driehaus Strategy Details - Driehaus prefers investing in stocks that are increasing in price rather than those in decline, focusing on momentum indicators such as the 50-day moving average [3] - The strategy incorporates a positive relative strength indicator, suggesting that stocks trading above their 50-day moving average are in an uptrend [4] Screening Parameters - The strategy utilizes specific screening parameters, including a Zacks Rank of 1 (Strong Buy) and a Momentum Score of A or B, to identify stocks with the best upside potential [6] - Key metrics include last 5-year average EPS growth rates above 2%, trailing 12-month EPS growth greater than 0, and a positive percentage change in the 50-day moving average [8] Company Insights - **Kinross Gold Corporation (KGC)**: Engaged in gold exploration and development across multiple countries, expected to benefit from rising gold prices and strong cash flows, with a trailing four-quarter earnings surprise of 17.4% on average [10] - **Willdan Group, Inc. (WLDN)**: Provides professional and consulting services, leveraging AI-focused infrastructure acquisitions to enhance profits, with a trailing four-quarter earnings surprise of 58.1% on average [11]

Company Overview - Franklin Covey Co. (FC) is currently experiencing significant activity in the options market, particularly with the Jan 16, 2026 $15.00 Call option showing high implied volatility, indicating potential for a major price movement [1] Implied Volatility Insights - Implied volatility reflects market expectations for future price movements, suggesting that investors anticipate a significant change in Franklin Covey's stock price, possibly due to an upcoming event [2] Analyst Sentiment - Franklin Covey holds a Zacks Rank of 3 (Hold) within the Consulting Services industry, which is in the top 19% of the Zacks Industry Rank. Over the past 60 days, there have been no increases in earnings estimates for the current quarter, with two analysts lowering their estimates, resulting in a drop in the Zacks Consensus Estimate from 18 cents to 3 cents per share [3] Trading Strategy Implications - The high implied volatility surrounding Franklin Covey may indicate a developing trading opportunity. Options traders often seek to sell premium on options with high implied volatility, aiming to benefit from the decay of the option's value if the stock does not move as much as anticipated [4]